Document Detail


A genotoxic screen: rapid analysis of cellular dose-response to a wide range of agents that either damage DNA or alter genome maintenance pathways.
MedLine Citation:
PMID:  15450423     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
SNP analysis has come to the forefront of genomics since the mouse and human genomes have been sequenced. High throughput functional screens are necessary to evaluate these sequence databases. Described here is a genotoxic screen: a rapid method that determines the cellular dose-response to a wide range of agents that either damage DNA or alter basic cellular pathways important for maintaining genomic integrity. Importantly, a single person utilizing standard tissue culture equipment may perform these assays composed of 20 agents that attack genomic integrity or maintenance at many different levels. Thus, a small lab may perform this screen to determine the integrity of a wide range of DNA repair, chromatin metabolism, and response pathways without the limitations of investigator bias. A genotoxic screen will be useful when analyzing cells with either known genetic alterations (generated directly by the investigator or derived from individuals with known mutations) or unknown genetic alterations (cells with spontaneous mutations such as cancer-derived cells). Screening many genotoxins at one time will aid in determining the biological importance of these altered genes. Here we show the dose-response curves of mouse embryonic stem (ES) cells and HeLa cells exposed to 20 genotoxic agents. ES cells were chosen since they are amenable to genetic alteration by the investigator. HeLa cells were chosen since they were derived from cancer and are commonly used. Comparing the dose-response curves of these two cell lines show their relative sensitivity to these agents and helps define their genotoxic profile. As a part of phenomics, a large genotoxic profile database for cancer-derived cells, when integrated with other databases such as expression profiles and comparative genomic hybridization, may aid in maximizing the effectiveness of developing anti-cancer protocols.
Authors:
Teresa Marple; Han Li; Paul Hasty
Related Documents :
22576273 - 18f-flt and 125i-idurd uptake increase in human tumour cell lines induced by the thymid...
12051763 - Ceramide promotes the death of human cervical tumor cells in the absence of biochemical...
24378843 - Orchestrating b cell lymphopoiesis through interplay of il-7 receptor and pre-b cell re...
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Mutation research     Volume:  554     ISSN:  0027-5107     ISO Abbreviation:  Mutat. Res.     Publication Date:  2004 Oct 
Date Detail:
Created Date:  2004-09-28     Completed Date:  2004-11-02     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  0400763     Medline TA:  Mutat Res     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  253-66     Citation Subset:  IM    
Affiliation:
The Department of Molecular Medicine, The University of Texas Health Science Center at San Antonio, 15355 Lambda Drive, 78245-3207, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Alkylating Agents / toxicity
Animals
Cell Line
DNA Damage*
DNA Topoisomerases, Type I / antagonists & inhibitors
Dose-Response Relationship, Drug
Dose-Response Relationship, Radiation
Enzyme Inhibitors / pharmacology
Genome*
Hela Cells
Humans
Mice
Grant Support
ID/Acronym/Agency:
R01 CA76317-05A1/CA/NCI NIH HHS; T32 CA86800-03/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Alkylating Agents; 0/Enzyme Inhibitors; EC 5.99.1.2/DNA Topoisomerases, Type I

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The ATM-SMC1 pathway is essential for activation of the chromium[VI]-induced S-phase checkpoint.
Next Document:  Identification of genetic polymorphisms of CYP2S1 in a Finnish Caucasian population.